PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Otava Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Otava Ltd Introduces New 11beta-hydroxysteroid Dehydrogenase Type 1 Target-focused Library - OTAVA Ltd offers new 11beta-hydroxysteroid dehydrogenase type 1 target-focused library containing 1,060 compounds which has been designed with receptor-based approach that included docking of Drug-like Green Collection in the active site of human 11
Otava Ltd Introduces New 11beta-hydroxysteroid Dehydrogenase Type 1 Target-focused Library

 

NewswireToday - /newswire/ - Toronto, Ontario, Canada, 2014/11/14 - OTAVA Ltd offers new 11beta-hydroxysteroid dehydrogenase type 1 target-focused library containing 1,060 compounds which has been designed with receptor-based approach that included docking of Drug-like Green Collection in the active site of human 11.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1, 11beta-HSD1) is an NADPH-dependent enzyme, which catalyses conversion of inactive glucocorticoids 11-dehydrocorticosterone and cortisone to active corticosterone and cortisol and vice versa. 11beta-HSD1 is also implicated in the regulation of glucocorticoid access to nuclear receptors.

Chronically increased levels of glucocorticoids are associated with the development of obesity, diabetes, cardiovascular disease (the metabolic syndrome) and impairments in memory. Dysregulation of 11beta-HSD1 has been reported to be involved in all of these human pathologies. It was demonstrated that the inhibition of 11beta-HSD1 activity decreased hypertension, insulin resistance, glucose intolerance, and hypertriglyceridemia. Therefore, 11beta-HSD1 is an attractive drug target for the treatment of the metabolic syndrome and cognitive impairment.
OTAVA Ltd. offers new 11beta-hydroxysteroid dehydrogenase type 1 target-focused library containing 1,060 compounds which has been designed with receptor-based approach that included docking of Drug-like Green Collection in the active site of human 11beta-HSD1 (PDB ID: 4C7K) and filtering by score values and hydrogen bonds formed between ligand and key residues of the 11beta-HSD1 active site. The library comprises drug-like compounds only.

The 11beta-HSD1 focused library from OTAVA is an excellent choice for drug discovery in endocrine and metabolic disorders treatment.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Otava Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Otava Ltd Introduces New 11beta-hydroxysteroid Dehydrogenase Type 1 Target-focused Library

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Andriy Petrenko - OtavaChemicals.com 
416-549-8030 info[.]otavachemicals.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Otava Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Otava Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)